Rémy Cointreau (RMC) Q2 25/26 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q2 25/26 TU earnings summary
31 Oct, 2025Executive summary
H1 organic sales declined 4.2% year-over-year, with Q2 down 11% due to adverse phasing and challenging macroeconomic conditions, especially in China.
Americas saw strong sales growth (+12.8%), driven by Cognac, while APAC sales fell 14.8% due to significant declines in China; EMEA declined 9.2% amid subdued demand.
Group reported H1 sales of €489.6 million, down 8.3% reported and 4.2% organic.
Guidance for 2025-26 was lowered, with organic sales growth now expected to be stable to low single digits and COP to decline by low double digits to mid-teens.
Financial highlights
H1 sales: €489.6 million, down 8.3% reported and 4.2% organic; negative currency impact of 4.1%.
Q2 sales dropped 11% organically, with Cognac down 13.5%, Liqueurs & Spirits down 5.3%, and Partner Brands down 28.7%.
Cognac H1 organic sales: -7.6% (volume +0.7%, price-mix -8.4%); Liqueurs & Spirits H1 organic sales: +4.1% (volume +5.2%, price-mix -1.0%).
Partner Brands represented 1.5% of group sales, down 35.7% in H1.
Currency impact on H1 sales: -€21.7 million, mainly from USD, CNY, and CAD.
Outlook and guidance
Full-year organic sales now expected to be stable to up low single digits, revised from mid-single digit growth.
Organic COP expected to decline low double digit to mid-teens, reflecting tariffs and pricing actions.
Tariffs net impact updated to €25 million on COP (China €5 million, US €20 million), with mitigation plans in place.
Currency effects expected to reduce sales by €50–60 million and operating profit by €25–30 million.
Latest events from Rémy Cointreau
- Q3 organic sales up 2.8% as U.S. and EMEA gains offset APAC and China weakness.RMC
Q3 2026 TU3 Feb 2026 - Q1 sales dropped 15.6% organically, with gradual recovery and cost controls underway.RMC
Q1 24/25 TU3 Feb 2026 - Sales and profit dropped, but cost savings and recovery with high single-digit growth are targeted.RMC
H2 23/241 Feb 2026 - H1 sales dropped 15.9% organically, triggering revised guidance and a major cost-cutting plan.RMC
H1 24/25 TU18 Jan 2026 - Sales and profit dropped, but margins held up due to aggressive cost controls.RMC
H1 24/2512 Jan 2026 - Q3 sales fell 21.5% organically; full-year decline near 18% with margin guidance held.RMC
Q3 24/25 TU9 Jan 2026 - Sales fell 18% organically; margin guidance held, cost savings and tariff risks remain.RMC
Q4 24/25 TU29 Nov 2025 - Sales and profit declined, but transformation and investment in recovery continue.RMC
H1 25/2627 Nov 2025 - Sales and profit fell sharply, but cost savings and a US rebound support cautious optimism.RMC
H2 24/2521 Nov 2025